Welcome to our dedicated page for TALPHERA SEC filings (Ticker: TLPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Talphera, Inc. filings document the regulatory record for a Nasdaq-listed specialty pharmaceutical company focused on medically supervised therapies. Recent Form 8-K reports cover financial results, corporate updates, private placements of common stock and pre-funded warrants, board appointments, equity-plan matters and Nasdaq listing-compliance notices.
The company’s proxy materials describe stockholder voting matters, director elections, executive compensation, equity awards and employee stock plan approvals. Talphera’s filings also identify its Delaware incorporation, Nasdaq Capital Market listing, registered common stock and capital-structure disclosures relevant to its pharmaceutical development business.
Talphera, Inc. reported another loss-making quarter as it continues to focus all resources on developing its nafamostat-based anticoagulant Niyad for dialysis settings. For the three months ended June 30, 2026, the company recorded a net loss of $4.3 million, compared with $3.5 million a year earlier; the six‑month net loss was $6.9 million.
Cash, cash equivalents and short‑term investments totaled $17.1 million as of June 30 2026, down from $20.4 million at year‑end, after using $7.3 million in operating cash in the first half and raising $3.8 million via a private placement of common stock and pre‑funded warrants. The NEPHRO CRRT registrational trial of Niyad is ongoing, with enrollment completion expected in 2026.
Management states that recurring losses, negative operating cash flows and limited cash resources raise substantial doubt about Talphera’s ability to continue as a going concern. The company expects to need additional capital to fund planned operations within 12 months of the report’s filing and outlines potential equity, debt, partnering or asset‑monetization options, while noting these plans are not within its full control.
Talphera, Inc. reported second quarter 2026 results and development progress for Niyad, its nafamostat-based anticoagulant for continuous renal replacement therapy (CRRT). The NEPHRO CRRT registrational study reached 75% enrollment, with all target clinical sites activated and completion expected this year. The 2026 KDIGO guideline for acute kidney injury and acute kidney disease cites nafamostat as an acceptable regional anticoagulant during CRRT, and updated market research estimates about 200,000 U.S. CRRT procedures in 2027, a 21% increase over prior estimates.
For the quarter ended June 30, 2026, Talphera recorded no revenue and a net loss attributable to common shareholders of $4.3 million, or $0.06 per share, compared with a net loss of $3.5 million, or $0.10 per share, a year earlier. Combined research and development and selling, general and administrative expenses were $3.9 million, up from $3.7 million, primarily due to higher Niyad development costs. Cash, cash equivalents and investments totaled $17.1 million as of June 30, 2026, versus $20.4 million at December 31, 2025. Total stockholders’ equity was $14.4 million at June 30, 2026.
Rosalind Advisors Inc., Rosalind Master Fund L.P. and related managers reported beneficial ownership in Talphera, Inc. common shares on a passive Schedule 13G/A basis. Rosalind Master Fund L.P. may be deemed to beneficially own 5,169,501 shares of common stock, which the filing states represents approximately 9.96% of Talphera’s common stock, based on 51,899,648 shares outstanding as of April 24, 2026.
The position excludes 7,743,681 additional shares issuable upon exercise of warrants and pre-funded warrants because these securities contain a 9.99% beneficial ownership blocker, preventing exercise to the extent it would push ownership above that level. As a result, the reporting persons state they were not able to exercise any of the warrants at the measurement date and that certain parties, including the advisor and portfolio manager, disclaim beneficial ownership of the shares held by the fund.
TALPHERA, INC. director Mark A. Wan reported equity awards that increase his direct stake in the company. He received 5,100 shares of common stock as a grant, bringing his direct holdings to 13,959 shares. He was also granted options to buy 30,700 shares of common stock at an exercise price of $0.98 per share, expiring on June 21, 2036. The filing notes that the 5,100 restricted stock units and all of the option shares vest in full on the first anniversary of the grant date, as long as he continues to provide service to TALPHERA.
TALPHERA, INC. director Joseph Todisco reported equity awards under the company’s compensation program. He acquired 5,100 shares of common stock at no cost, bringing his direct holdings to 11,497 shares after the transaction.
He was also granted a director stock option covering 30,700 shares of common stock at an exercise price of $0.98 per share, expiring on June 21, 2036. According to the footnotes, 100% of these stock units and option shares vest on the first anniversary of the June 22, 2026 grant date, subject to his continuous service to the company.
TALPHERA, INC. director Abhinav Jain reported equity compensation grants consisting of restricted stock units and stock options. He received 5,100 shares of common stock as a grant, bringing his direct holdings to 12,412 shares after the transaction. These awards carry no cash purchase price.
On the same date, he was granted stock options for 30,700 shares of common stock at an exercise price of $0.98 per share, expiring on June 21, 2036. Footnotes state that 100% of the restricted stock units and 100% of the option shares vest on the first anniversary of the grant date, subject to his continuous service to the company.
TALPHERA, INC. director Stephen J. Hoffman received new equity awards as part of his compensation. On June 22, 2026, he was granted 5,100 shares of common stock at no cost, increasing his direct common stock holdings to 13,959 shares after the award.
He also received a stock option for 30,700 shares of common stock with an exercise price of $0.98 per share, expiring on June 21, 2036. Footnotes state that all 5,100 restricted stock units and all 30,700 option shares will vest in full on the first anniversary of the grant date, provided he continues to serve the company.
TALPHERA, INC. director Jill Marie Broadfoot reported equity awards consisting of restricted stock units and stock options. She received 5,100 shares of common stock as a grant at no cost and now holds 13,647 common shares directly. She was also granted options on 30,700 shares at an exercise price of $0.98 per share, expiring in 2036. Both the restricted stock units and the option grant vest in full on the first anniversary of the grant date, contingent on her continuous service with the company.
TALPHERA, INC. director Marina Bozilenko received equity compensation in the form of restricted stock units and stock options. She was granted 5,100 restricted stock units, each representing one share of common stock, all vesting on the first anniversary of the grant date, subject to her continuous service.
She was also granted options to purchase 30,700 shares of common stock at an exercise price of $0.98 per share, with 100% of the option shares vesting on the one-year anniversary of the grant date, also contingent on continued service. Following these awards, she directly holds 14,147 shares of common stock and 30,700 options.
TALPHERA, INC. director Adrian Adams received new equity awards. On June 22, 2026, he was granted 5,100 restricted stock units, each representing the right to receive one share of common stock. These RSUs vest 100% on the first anniversary of the grant, if he remains in continuous service.
Adams also received a stock option for 30,700 shares of common stock at an exercise price of $0.98 per share, expiring on June 21, 2036. The option vests in full one year after the grant date, subject to his continued service, and brings his direct common stock holdings to 22,709 shares after the RSU grant.